Teck Resources Limited (TECK) Forms $26.65 Double Top; 12 Analysts Bullish Agios Pharmaceuticals, Inc. (AGIO)

April 20, 2018 - By wolcottdaily

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Logo

Among 16 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Agios Pharmaceuticals had 45 analyst reports since July 23, 2015 according to SRatingsIntel. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has “Buy” rating given on Tuesday, August 1 by Oppenheimer. Canaccord Genuity upgraded the stock to “Buy” rating in Monday, June 13 report. The rating was maintained by Roth Capital on Monday, November 9 with “Neutral”. The firm has “Buy” rating by Cowen & Co given on Tuesday, June 6. On Thursday, June 1 the stock rating was maintained by Oppenheimer with “Buy”. BTIG Research initiated Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Friday, August 19 with “Neutral” rating. The stock has “Buy” rating by SunTrust on Wednesday, March 30. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) earned “Hold” rating by Roth Capital on Wednesday, August 5. The firm earned “Buy” rating on Wednesday, May 18 by Suntrust Robinson. RBC Capital Markets maintained it with “Buy” rating and $80.0 target in Wednesday, November 1 report. See Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) latest ratings:

11/04/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $80 New Target: $95 Maintain
15/02/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $76 New Target: $85 Maintain
15/02/2018 Broker: Credit Suisse Rating: Buy New Target: $80.0 Maintain
14/02/2018 Broker: RBC Capital Markets Rating: Buy New Target: $88.0 Maintain
19/11/2017 Broker: SunTrust Rating: Buy New Target: $80.0 Maintain
01/11/2017 Broker: RBC Capital Markets Rating: Buy New Target: $80.0 Maintain
02/11/2017 Broker: Credit Suisse Rating: Outperform Old Target: $61 New Target: $66 Maintain

Teck Resources Limited (TECK) formed double top with $27.98 target or 5.00% above today’s $26.65 share price. Teck Resources Limited (TECK) has $14.71 billion valuation. The stock decreased 1.22% or $0.33 during the last trading session, reaching $26.65. About 2.79 million shares traded. Teck Resources Limited (NYSE:TECK) has risen 16.59% since April 20, 2017 and is uptrending. It has outperformed by 5.04% the S&P500.

Analysts await Teck Resources Limited (NYSE:TECK) to report earnings on April, 24 before the open. They expect $1.09 earnings per share, up 23.86% or $0.21 from last year’s $0.88 per share. TECK’s profit will be $601.48M for 6.11 P/E if the $1.09 EPS becomes a reality. After $0.95 actual earnings per share reported by Teck Resources Limited for the previous quarter, Wall Street now forecasts 14.74% EPS growth.

Among 12 analysts covering Teck Resources (NYSE:TECK), 11 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Teck Resources has $29.0 highest and $15.6 lowest target. $25.27’s average target is -5.18% below currents $26.65 stock price. Teck Resources had 16 analyst reports since December 5, 2016 according to SRatingsIntel. The stock of Teck Resources Limited (NYSE:TECK) earned “Sector Outperform” rating by IBC on Friday, November 17. On Wednesday, April 19 the stock rating was maintained by Credit Suisse with “Outperform”. Axiom Capital initiated the shares of TECK in report on Monday, September 18 with “Sell” rating. The rating was upgraded by Citigroup to “Buy” on Monday, December 5. The company was upgraded on Tuesday, December 20 by Macquarie Research. The company was upgraded on Wednesday, October 4 by Bank of America. Deutsche Bank upgraded Teck Resources Limited (NYSE:TECK) on Tuesday, March 21 to “Buy” rating. The firm earned “Buy” rating on Tuesday, December 20 by M Partners. Bank of America downgraded the stock to “Neutral” rating in Friday, June 9 report. Berenberg upgraded the shares of TECK in report on Wednesday, March 22 to “Buy” rating.

Since January 10, 2018, it had 1 buy, and 19 sales for $16.87 million activity. Biller Scott sold $228,128 worth of stock or 3,000 shares. Another trade for 25,000 shares valued at $1.87 million was sold by Hoerter Steven L.. $1.01M worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was sold by Schenkein David P on Monday, April 2. On Friday, January 12 the insider Alenson Carman sold $161,250. Bowden Christopher also sold $164,661 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares. $557,396 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares were sold by Foster-Cheek Kaye I. Scadden David had bought 200 shares worth $16,688.

The stock increased 0.30% or $0.26 during the last trading session, reaching $88.29. About 288,185 shares traded. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 41.40% since April 20, 2017 and is uptrending. It has outperformed by 29.85% the S&P500.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $5.06 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>